NCT06545877 REKOVELLE PEN for S.C. Injection General Drug Use Survey (Controlled Ovarian Stimulation in Assisted Reproductive Technologies)
| NCT ID | NCT06545877 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ferring Pharmaceuticals |
| Condition | Infertility |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2022-09-16 |
| Primary Completion | 2026-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2022-09-16 with a primary completion date of 2026-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This survey targets controlled ovarian stimulation with this drug for the development of multiple oocytes in women undergoing assisted reproduction (ART) such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).
Eligibility Criteria
Inclusion Criteria: * Participants who received the REKOVELLE in controlled ovarian stimulation in assisted reproductive technologies and have consented to participate in the survey. Exclusion Criteria: * No exclusion criteria because data are collected under conditions of use in daily practice.
Contact & Investigator
Global Clinical Compliance
STUDY DIRECTOR
Ferring Pharmaceuticals
Frequently Asked Questions
Who can join the NCT06545877 clinical trial?
This trial is open to female participants only, studying Infertility. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06545877 currently recruiting?
Yes, NCT06545877 is actively recruiting participants. Contact the research team at DK0-Disclosure@ferring.com for enrollment information.
Where is the NCT06545877 trial being conducted?
This trial is being conducted at Omitama, Japan.
Who is sponsoring the NCT06545877 clinical trial?
NCT06545877 is sponsored by Ferring Pharmaceuticals. The principal investigator is Global Clinical Compliance at Ferring Pharmaceuticals. The trial plans to enroll 500 participants.